805 related articles for article (PubMed ID: 16622691)
1. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
Kosmas C; Tsavaris N; Panopoulos C; Vadiaka M; Stavroyianni N; Kourelis T; Malamos N; Antonopoulos M; Kalofonos HP
Eur J Cancer; 2001 May; 37(8):972-8. PubMed ID: 11334721
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
Georgoulias V; Kouroussis C; Agelidou A; Boukovinas I; Palamidas P; Stavrinidis E; Polyzos A; Syrigos K; Veslemes M; Toubis M; Ardavanis A; Tselepatiotis E; Vlachonikolis I;
Br J Cancer; 2004 Aug; 91(3):482-8. PubMed ID: 15238986
[TBL] [Abstract][Full Text] [Related]
6. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
Kosmas C; Tsavaris NB; Makatsoris T; Onyenadum A; Vadiaka M; Stavroyianni N; Sepsas E; Dimitropoulos D; Rokana S; Kalofonos HP
Int J Cancer; 2002 Mar; 98(1):141-7. PubMed ID: 11857398
[TBL] [Abstract][Full Text] [Related]
7. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
[TBL] [Abstract][Full Text] [Related]
8. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Ohyanagi F; Taguchi F; Horai T; Kasahara K; Takeda Y; Shibata K; Shirosaki H; Nishio M
Jpn J Clin Oncol; 2006 Sep; 36(9):547-51. PubMed ID: 16870693
[TBL] [Abstract][Full Text] [Related]
10. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.
Hainsworth JD; Burris HA; Litchy S; Erland JB; Hon JK; Brierre JE; Greco FA
Cancer; 2000 Mar; 88(6):1353-8. PubMed ID: 10717616
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
[TBL] [Abstract][Full Text] [Related]
14. Challenging the platinum combinations in the chemotherapy of NSCLC.
Douillard JY; Eckardt J; Scagliotti GV
Lung Cancer; 2002 Dec; 38 Suppl 4():21-8. PubMed ID: 12480191
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study.
Pectasides D; Mylonakis N; Farmakis D; Nikolaou M; Koumpou M; Katselis I; Gaglia A; Kostopoulou V; Karabelis A; Kosmas C
Anticancer Res; 2003; 23(5b):4205-11. PubMed ID: 14666626
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Rocha Lima CM; Rizvi NA; Zhang C; Herndon JE; Crawford J; Govindan R; King GW; Green MR;
Ann Oncol; 2004 Mar; 15(3):410-8. PubMed ID: 14998842
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma.
Kosmas C; Tsavaris NB; Polyzos A; Kalofonos HP; Sepsas E; Malamos NA; Vadiaka M; Dosios T; Antonopoulos MJ
Cancer; 2000 Aug; 89(4):774-82. PubMed ID: 10951340
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
Cobo M; Gutiérrez V; Alcaide J; Alés I; Villar E; Gil S; Durán G; Martínez J; Carabantes F; Bretón JJ; Benavides M
Lung Cancer; 2007 May; 56(2):255-62. PubMed ID: 17276537
[TBL] [Abstract][Full Text] [Related]
19. [A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].
Ryo H; Toyama K; Isobe K; Sugino K; Sano G; Yamada H; Hiroi M; Hojyo T; Kimura K
Gan To Kagaku Ryoho; 2003 Feb; 30(2):237-42. PubMed ID: 12610872
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Font A; Sanchez JM; Rosell R; Taron M; Martinez E; Guillot M; Manzano JL; Margeli M; Barnadas A; Abad A
Lung Cancer; 2002 Aug; 37(2):213-8. PubMed ID: 12140145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]